151 related articles for article (PubMed ID: 24510745)
21. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
22. Environmental effect assessment for sexual endocrine-disrupting chemicals: Fish testing strategy.
Knacker T; Boettcher M; Frische T; Rufli H; Stolzenberg HC; Teigeler M; Zok S; Braunbeck T; Schäfers C
Integr Environ Assess Manag; 2010 Oct; 6(4):653-62. PubMed ID: 20872646
[TBL] [Abstract][Full Text] [Related]
23. Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors.
Keane KA; Parker GA; Regan KS; Picut C; Dixon D; Creasy D; Giri D; Hukkanen RR
Toxicol Pathol; 2015 Dec; 43(8):1047-63. PubMed ID: 25948506
[TBL] [Abstract][Full Text] [Related]
24. An exposure:activity profiling method for interpreting high-throughput screening data for estrogenic activity--proof of concept.
Becker RA; Friedman KP; Simon TW; Marty MS; Patlewicz G; Rowlands JC
Regul Toxicol Pharmacol; 2015 Apr; 71(3):398-408. PubMed ID: 25656492
[TBL] [Abstract][Full Text] [Related]
25. An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Slone TW; Makovec GT; Frame SR; Davis LG
Toxicol Sci; 1998 Nov; 46(1):45-60. PubMed ID: 9928668
[TBL] [Abstract][Full Text] [Related]
26. Uncertainties for endocrine disrupters: our view on progress.
Daston GP; Cook JC; Kavlock RJ
Toxicol Sci; 2003 Aug; 74(2):245-52. PubMed ID: 12730617
[TBL] [Abstract][Full Text] [Related]
27. Update of OECD DART guidelines with endocrine disruptor relevant endpoints: Practical considerations.
Beekhuijzen M; van Otterdijk F; Wieland W; van Tuyl M; Rijcken RP; Peter B; Emmen H
Reprod Toxicol; 2016 Sep; 64():64-71. PubMed ID: 27063183
[TBL] [Abstract][Full Text] [Related]
28. Assessment of in vivo assays for endocrine disruption.
Clode SA
Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):35-43. PubMed ID: 16522518
[TBL] [Abstract][Full Text] [Related]
29. Endocrine profiling and prioritization of environmental chemicals using ToxCast data.
Reif DM; Martin MT; Tan SW; Houck KA; Judson RS; Richard AM; Knudsen TB; Dix DJ; Kavlock RJ
Environ Health Perspect; 2010 Dec; 118(12):1714-20. PubMed ID: 20826373
[TBL] [Abstract][Full Text] [Related]
30. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS).
Melching-Kollmuss S; Bothe K; Charlton A; Gangadharan B; Ghaffari R; Jacobi S; Marty S; Marxfeld HA; McInnes EF; Sauer UG; Sheets LP; Strupp C; Tinwell H; Wiemann C; Botham PA; van Ravenzwaay B
Crit Rev Toxicol; 2023 Jul; 53(6):339-371. PubMed ID: 37554099
[TBL] [Abstract][Full Text] [Related]
31. Identifying reference chemicals for thyroid bioactivity screening.
Wegner S; Browne P; Dix D
Reprod Toxicol; 2016 Oct; 65():402-413. PubMed ID: 27589887
[TBL] [Abstract][Full Text] [Related]
32. Current limitations and recommendations to improve testing for the environmental assessment of endocrine active substances.
Coady KK; Biever RC; Denslow ND; Gross M; Guiney PD; Holbech H; Karouna-Renier NK; Katsiadaki I; Krueger H; Levine SL; Maack G; Williams M; Wolf JC; Ankley GT
Integr Environ Assess Manag; 2017 Mar; 13(2):302-316. PubMed ID: 27791330
[TBL] [Abstract][Full Text] [Related]
33. Weight-of-the-evidence evaluation of 2,4-D potential for interactions with the estrogen, androgen and thyroid pathways and steroidogenesis.
Neal BH; Bus J; Marty MS; Coady K; Williams A; Staveley J; Lamb JC
Crit Rev Toxicol; 2017 May; 47(5):345-401. PubMed ID: 28303741
[TBL] [Abstract][Full Text] [Related]
34. Developing scientific confidence in HTS-derived prediction models: lessons learned from an endocrine case study.
Cox LA; Popken D; Marty MS; Rowlands JC; Patlewicz G; Goyak KO; Becker RA
Regul Toxicol Pharmacol; 2014 Aug; 69(3):443-50. PubMed ID: 24845243
[TBL] [Abstract][Full Text] [Related]
35. Endpoint sensitivity in fish endocrine disruption assays: regulatory implications.
Dang Z; Li K; Yin H; Hakkert B; Vermeire T
Toxicol Lett; 2011 Apr; 202(1):36-46. PubMed ID: 21295121
[TBL] [Abstract][Full Text] [Related]
36. Endpoint sensitivity in Amphibian Metamorphosis Assay.
Dang Z
Ecotoxicol Environ Saf; 2019 Jan; 167():513-519. PubMed ID: 30384058
[TBL] [Abstract][Full Text] [Related]
37. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
38. Efficient testing strategies for evaluation of xenobiotics with neuroendocrine activity.
Calamandrei G; Maranghi F; Venerosi A; Alleva E; Mantovani A
Reprod Toxicol; 2006 Aug; 22(2):164-74. PubMed ID: 16781111
[TBL] [Abstract][Full Text] [Related]
39. Approaches to the assessment of toxicity data with endpoints related to endocrine disruption.
Harvey PW; Johnson I
J Appl Toxicol; 2002; 22(4):241-7. PubMed ID: 12210541
[TBL] [Abstract][Full Text] [Related]
40. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
